Arkolith/Insider Trading/ARWR/Form 4

Anzalone Christopher Richard

Chief Executive Officer, DirectorARROWHEAD PHARMACEUTICALS, INC. (ARWR) · full profile →Form 4 · filed Mar 17, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$775K
Net Open-Market Flow
-$775K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 13, 2025Sell(S)51K$15.07$775K4.1M
Mar 13, 2025Grant(A)340K—$04.1M

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-25-013210) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML